CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 134 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00027183
NCT00027183N/ACompleted

Role of Exotoxins in the Pathogenesis of Pseudomonas Aeruginosa

National Heart, Lung, and Blood Institute (NHLBI)·observational·Posted Nov 28, 2001·Updated Jun 6, 2022

In Brief

An observational study for Pseudomonas Infection and Cystic Fibrosis. Completed, enrolled 134 participants across 1 site.

Detailed Summary

Some bacteria that cause disease can produce toxic substances that may worsen the disease. Pseudomonas aeruginosa is a bacteria that can produce a variety of toxins and is of special interest for patients with cystic fibrosis and repeated long term lung infections. The goal of this study is to determine whether specific toxins produced by Pseudomonas aeruginosa may be important in the disease process of chronic lung infections of patients with cystic fibrosis. This study will attempt to measure bacterial production of toxins in blood and sputum and immune system response to toxins in the blood....

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 28, 2001
Enrollment StartMar 17, 1998
Primary CompletionSep 7, 2006
Study CompletionDec 28, 2018
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 24.6 years ago